Your cart
Your cart is empty
Continue shopping
Pharmacor
I-Pantoprazole
Sale price
$2.10
-33%
Regular price
$3.09
Regular price
$2.10
Unit price
per
Low stock
In stock, ready to ship
Product Sold Out
More Information (API / 40mg x 30 Tabs)
Active Ingredients
pantoprazole sodium sesquihydrate 45.4mg Equivalent: pantoprazole 40mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) Duodenal ulcer; ii) Gastric ulcer; iii) Gastro-oesophageal reflux disease (GORD): Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD; Reflux oesophagitis; iv) Gastrointestinal lesions refractory H2 blockers; v) Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
Tablet Description
Yellow to pale yellow coloured oval, biconvex enteric coated tablets plain on both sides.
Storage Conditions
Additional Information
Warnings
More Information (Sigma / 40mg x 30 Tabs)
Active Ingredients
pantoprazole sodium sesquihydrate 45.4mg Equivalent: pantoprazole 40mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) Duodenal ulcer; ii) Gastric ulcer; iii) Gastro-oesophageal reflux disease (GORD): Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD; Reflux oesophagitis; iv) Gastrointestinal lesions refractory H2 blockers; v) Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
Tablet Description
Yellow to pale yellow coloured oval, biconvex enteric coated tablets plain on both sides.
Storage Conditions
Additional Information
Warnings
More Information (Symbion / 40mg x 30 Tabs)
Active Ingredients
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
Tablet Description
Yellow to pale yellow coloured oval, biconvex enteric coated tablets plain on both sides.
Storage Conditions
Additional Information
Warnings
More Information (CH2 / 40mg x 30 Tabs)
Active Ingredients
pantoprazole sodium sesquihydrate 45.4mg Equivalent: pantoprazole 40mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) Duodenal ulcer; ii) Gastric ulcer; iii) Gastro-oesophageal reflux disease (GORD): Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD; Reflux oesophagitis; iv) Gastrointestinal lesions refractory H2 blockers; v) Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.
3. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
Tablet Description
Yellow to pale yellow coloured oval, biconvex enteric coated tablets plain on both sides.
Storage Conditions
Additional Information
Warnings
Connecting Care, Simplifying Supply.
At Pharmacor, we bridge the gap between healthcare providers and seamless supply solutions, ensuring care is always within reach.
Image
Product Name
Wholesaler
Strength/Pack Size
Product Info
